Figure 2.
Figure 2. Pie chart illustrating the distribution of the most frequent cytogenetics defining intermediate-risk AML according to the ELN recommendations.1 These data are based on 1681 intermediate-risk AML patients treated within the AMLSG AMLHD93, AMLHD98A (www.ClinicalTrials.gov identifier NCT00146120), AMLHD98B, AMLSG 06-04, and AMLSG 07-04 (www.ClinicalTrials.gov identifier NCT00151242) studies.

Pie chart illustrating the distribution of the most frequent cytogenetics defining intermediate-risk AML according to the ELN recommendations.1  These data are based on 1681 intermediate-risk AML patients treated within the AMLSG AMLHD93, AMLHD98A (www.ClinicalTrials.gov identifier NCT00146120), AMLHD98B, AMLSG 06-04, and AMLSG 07-04 (www.ClinicalTrials.gov identifier NCT00151242) studies.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal